STEP ONE: SELECT CLINICAL SCENARIO *ADDITION (Row I)* *OR* *REPLACEMENT (Row II)*	**STEP TWO: GATHER CLINICAL OUTCOMES** - Data should be obtained from prospective randomized trials. - Record **BIOMARKER PREVALENCE** specific to study population (Ensuring consistent patient demographics, tumor staging/characteristics) - Record **MEDIAN PFS** and **MEDIAN OS (IF AVAILABLE)** for targeted treatment AND *specific* standard treatment regimen. -- Record 95% confidence interval of clinical outcome values if given		**STEP THREE: GATHER ADDITIONAL DATA** **COSTS** - Obtain cost data from Medicare reimbursement amounts (ie RED BOOK pricing). - Scale data to unit cost/ yr - Select range for sensitivity analysis based on - If data does not exist for emerging therapy, please use surrogate data from similar pharmaceutical class.	**HRQOL** - Ideally, HRQOL data will be reported as secondary outcome in randomized trials. - Alternatively, HRQOL data can be gathered from literature search for meta-analysis for specific cancer type (e.g. [25]) - Alternatively, HRQOL data can be estimated from published compendiums (e.g. [27])
	Median Biomarker Prevalence: ___ ; **95% CI: [___ to ___]**			
(I) ADDITION of Targeted Therapy to Standard. *For example, Trastuzumab added to chemotherapy for HER2+ breast cancer.*	**Median PFS ____** **95% CI: [___ to ___]**		**- Cost of Test: ____; Range: [___ to ___]** **- Cost of Targeted Therapy: ___ ;** **Range: [___ to ___]** **- Cost of Standard Therapy: ____**	**- HRQOL of Targeted Therapy: ___ ;** **Range: [___ to ___]** **- HRQOL of Standard Therapy: ___;**
	Median OS ___ **95% CI: [___ to ___]**	*If OS is unavailable, please disregard outlined variables. Note that the calculation will then assume* *ΔOS ≈ ΔPFS*	**- Cost of Progressed Disease: ____** *Determine cost/ year from literature search of existing cost analysis, ensuring tumor staging/ characteristics consistency with clinical trial data.*	**- HRQOL of Progressed Disease: ___**
OR				
(II) REPLACEMENT of Standard with Targeted Therapy *For example, first-line Crizotinib therapy in NSCLC with ALK rearrangement*	**Median PFS ____** **95% CI: [___ to ___]**	**Duration of Std. Treatment ____ ; 95% CI: [___ to ___]**	**- Cost of Test: ____; Range: [___ to ___]** **- Cost of Targeted Therapy: ___ ;** **Range: [___ to ___]** **- Cost of Standard Therapy: ____**	**- HRQOL of Targeted Therapy: ___ ;** **Range: [___ to ___]** **- HRQOL of Standard Therapy: ___;**
	Median OS ___ **95% CI: [___ to ___]**	*If overall survival data unavailable, please disregard outlined variables. Note that this calculation will then assume* *ΔOS ≈ ΔPFS*	**- Cost of Progressed Disease: ____** *Determine cost/ year from literature search of existing cost analysis, ensuring tumor staging/ characteristics consistency with clinical trial data.*	**- HRQOL of Progressed Disease : ___** **- HRQOL of Stable Disease: ___**